GTX GTX 深 沪
等待开盘 10-11 09:30:00 美东时间
12.91
-0.110
-0.84%
华盛通- 最 高13.295
- 今 开13.02
- 成交量 180.97万股
- 最 低 12.86
- 昨 收 13.02
- 总市值 26.08亿
- 52周最高 14.015
- 市盈率 静 10.26
- 换手率 0.90%
- 52周最低 6.895
- 委 比 -86.69%
- 总股本 2.02亿
- 历史最高 19.53
- 量 比 0.80
- 振 幅 3.34%
- 历史最低 1.52
- 每 手 1
- 风险率 1.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
BWS Financial Maintains Buy on Garrett Motion, Raises Price Target to $18
BWS Financial analyst Hamed Khorsand maintains Garrett Motion (NASDAQ:GTX) with a Buy and raises the price target from $14 to $18.
10-01 00:31
Garrett Motion’s General Counsel Announces Retirement
The latest update is out from Garrett Motion ( ($GTX) ). On September 25, 2025,...
09-27 05:13
双“英”恩仇：英特尔和英伟达的三十年
153 陈永伟 北京时间9月19日凌晨，英伟达创始人黄仁勋与英特尔首席执行官陈立武共同召开了一场线上发布会。会上，黄仁勋宣布了一个爆炸性的消息：英伟达将向老对手...
09-26 23:45
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
Stifel Initiates Coverage On Garrett Motion with Buy Rating, Announces Price Target of $17.5
Stifel analyst Nathan Jones initiates coverage on Garrett Motion (NASDAQ:GTX) with a Buy rating and announces Price Target of $17.5.
09-19 21:36
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
Gain announced the start of the Phase 1b extension study for GT-02287, allowing participants to continue treatment for an additional nine months. The Phase 1b study enrolled 21 subjects, with the final participants completing the initial 90-day dosing in December 2025. Early results will be presented at the International Congress of Parkinson’s Disease in October. Additional 90-day data, including biomarkers and functional assessments, are expect...
09-18 11:41
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Gain Therapeutics announced that its Phase 1b clinical trial for GT-02287, a potential treatment for Parkinson's disease, has been extended by nine months for participants who completed the initial three-month study. The independent data monitoring committee (DMC) reviewed interim safety data and recommended continuing the study without changes. GT-02287, an orally administered, brain-penetrant small molecule, aims to restore lysosomal enzyme fun...
09-04 12:00
英伟达显卡用油散热，性能提升16%！DIY大神爆改版跑分登顶榜首
henry 发自 凹非寺 量子位 | 公众号 QbitAI 歪果仁也有自己的“手工耿”…… 一老哥用变速箱油和汽车变速箱冷却器DIY了一套显卡油冷散热。 在这套...
09-01 12:36
Garrett Motion Board Member Kevin Mahony Resigns
The latest announcement is out from Garrett Motion ( ($GTX) ). On August 27, 20...
08-29 21:53
